Miranda Siemienowicz
Research Subjects
Miranda Siemienowicz has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Annette McWilliams
Department of Respiratory Medicine Fiona Stanley Hospital Murdoch Western Australia Australia
2 shared publications Catherine M. Jones
I‐MED Radiology Brisbane Queensland Australia
2 shared publications- Diane M. Pascoe
Department of Radiology Royal Melbourne Hospital Melbourne Victoria Australia
2 shared publications - Fraser Brims
Curtin Medical School, Curtin University, Perth, Australia
2 shared publications - Hayley Barnes
Faculty of Medicine, Nursing, and Health Sciences, Monash University Monash Centre for Occupational and Environmental Health, School of Public Health and Preventive Medicine Melbourne, Victoria
2 shared publications - Mark W. McCusker
Department of Radiology Royal Melbourne Hospital Melbourne Victoria Australia
2 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 38, e16
Evaluating the efficacy of prednisolone for silicosis with progressive massive fibrosis in Australia: an observational pilot study
Background: There has been a resurgence of silicosis, particularly related to artificial stone. There are currently no treatments for silicosis beyond lung transplantation for end-stage disease. This study aimed to evaluate the efficacy of prednisolone in people with artificial stone-associated silicosis–progressive massive fibrosis (PMF).Methods: This was a pilot prospective observational clinical trial, assessing 3 months of prednisolone in adults with artificial stone–associated silicosis with PMF. Outcomes were assessed at 3 and 12 months.Results: Seven participants completed the study. Baseline positron emission tomography (PET) scans demonstrated increased fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in areas of PMF in all participants. All participants had a significant reduction in maximum standardized uptake value (SUVmax) following prednisolone at 3 months (pre-treatment mean SUVmax 6.7 [standard deviation (SD): 2.6], post-treatment mean SUVmax 4.2 [SD: 1.0], p = 0.012). There was also a non-significant reduction in the % of total lung parenchyma with SUV >1 (49.7% [SD: 36.4] to 45.8% [SD: 28.4], p = 0.527) and a significant reduction in SUV >2.5 (7.0% [SD: 6.3] to 2.4% [SD: 2.2], p = 0.038). There was a non-significant reduction in computed tomography ICOERD well-defined opacity profusion scores and large opacities. There was no significant difference in lung function or St. George's Respiratory Questionnaire. There were no serious adverse events.Conclusions: There are high levels of inflammation in silicosis-PMF as evidenced by 18F-FDG PET. Short-term prednisolone reduced 18F-FDG PET activity. This suggests a possible therapeutic pathway for people with silicosis-associated PMF in a population with no current treatments. Further research is required to determine the most appropriate immunosuppressive strategy and further assess longer-term outcomes.
- 4 June 2026
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 38, e16
Open AccessEvaluating the efficacy of prednisolone for silicosis with progressive massive fibrosis in Australia: an observational pilot study
Background: There has been a resurgence of silicosis, particularly related to artificial stone. There are currently no treatments for silicosis beyond lung transplantation for end-stage disease. This study aimed to evaluate the efficacy of prednisolone in people with artificial stone-associated silicosis–progressive massive fibrosis (PMF).Methods: This was a pilot prospective observational clinical trial, assessing 3 months of prednisolone in adults with artificial stone–associated silicosis with PMF. Outcomes were assessed at 3 and 12 months.Results: Seven participants completed the study. Baseline positron emission tomography (PET) scans demonstrated increased fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in areas of PMF in all participants. All participants had a significant reduction in maximum standardized uptake value (SUVmax) following prednisolone at 3 months (pre-treatment mean SUVmax 6.7 [standard deviation (SD): 2.6], post-treatment mean SUVmax 4.2 [SD: 1.0], p = 0.012). There was also a non-significant reduction in the % of total lung parenchyma with SUV >1 (49.7% [SD: 36.4] to 45.8% [SD: 28.4], p = 0.527) and a significant reduction in SUV >2.5 (7.0% [SD: 6.3] to 2.4% [SD: 2.2], p = 0.038). There was a non-significant reduction in computed tomography ICOERD well-defined opacity profusion scores and large opacities. There was no significant difference in lung function or St. George's Respiratory Questionnaire. There were no serious adverse events.Conclusions: There are high levels of inflammation in silicosis-PMF as evidenced by 18F-FDG PET. Short-term prednisolone reduced 18F-FDG PET activity. This suggests a possible therapeutic pathway for people with silicosis-associated PMF in a population with no current treatments. Further research is required to determine the most appropriate immunosuppressive strategy and further assess longer-term outcomes.
- Open Access
- 27 February 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 70 (3) , 294-303
Rationale for the Nodule Management Protocol of the Australian National Lung Cancer Screening Program
In July 2022, the Australian Medical Services Advisory Committee (MSAC) recommended the establishment of an Australian NLCSP (National Lung Cancer Screening Program), using low‐dose computed tomography (LDCT) for the early detection of lung cancer in asymptomatic high‐risk individuals. MSAC's recommendations for the NLCSP included core requirements as follows: (i) routine biennial screening, (ii) use of the PanCan risk prediction model for reporting baseline LDCT, and (iii) the use of the most recent version of Lung‐RADS for reporting follow‐up LDCT. Necessary adaptations were made to incorporate these requirements, resulting in a bespoke protocol for the Australian context. This article summarises the rationale and development of the NLCSP Nodule Management Protocol.
- 27 February 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 70 (3) , 294-303
Open AccessRationale for the Nodule Management Protocol of the Australian National Lung Cancer Screening Program
In July 2022, the Australian Medical Services Advisory Committee (MSAC) recommended the establishment of an Australian NLCSP (National Lung Cancer Screening Program), using low‐dose computed tomography (LDCT) for the early detection of lung cancer in asymptomatic high‐risk individuals. MSAC's recommendations for the NLCSP included core requirements as follows: (i) routine biennial screening, (ii) use of the PanCan risk prediction model for reporting baseline LDCT, and (iii) the use of the most recent version of Lung‐RADS for reporting follow‐up LDCT. Necessary adaptations were made to incorporate these requirements, resulting in a bespoke protocol for the Australian context. This article summarises the rationale and development of the NLCSP Nodule Management Protocol.
- Open Access
- 16 August 2025
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 69 (7) , 740-744
The Australian National Lung Cancer Screening Program: A Radiologist's Perspective
On July 1, 2025, Australia commenced screening eligible participants in a ground‐breaking health initiative with the launch of a national lung cancer screening program (NLCSP). Designed for individuals at high risk, this program aims to promote early detection and improve both survival rates and treatment outcomes. Radiology will serve as a cornerstone of the program's success. This article provides a comprehensive overview from the radiologist's perspective.
- 16 August 2025
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 69 (7) , 740-744
Open AccessThe Australian National Lung Cancer Screening Program: A Radiologist's Perspective
On July 1, 2025, Australia commenced screening eligible participants in a ground‐breaking health initiative with the launch of a national lung cancer screening program (NLCSP). Designed for individuals at high risk, this program aims to promote early detection and improve both survival rates and treatment outcomes. Radiology will serve as a cornerstone of the program's success. This article provides a comprehensive overview from the radiologist's perspective.
- Open Access
- 29 May 2025
- Published by Wiley in Respirology
- Vol. 30 (7) , 558-573
The TSANZ Practical Guide for Clinicians in the Management of Screen‐ and Incidentally‐Detected Nodules
The increasing adoption of lung cancer screening programs and advancements in imaging technologies has significantly increased the detection of pulmonary nodules, both incidentally and through screening. This document provides a comprehensive guide for clinicians to address the complexities of managing indeterminate pulmonary nodules (IPNs), emphasising person‐centred and multidisciplinary care. IPNs are categorised based on size and morphology, with specific guidelines for malignancy risk stratification, diagnostic evaluation, and follow‐up. Dedicated lung nodule evaluation teams (LNETs) and nodule multidisciplinary meetings (MDMs) play a critical role in ensuring guideline adherence, streamlining the diagnostic pathway, reducing unnecessary investigations, and improving outcomes. Structured IPN programs have demonstrated benefits in early lung cancer detection, improved detection of early‐stage lung cancer, and reduced delays to treatment initiation. Effective management strategies include use of standardised reporting templates, utilising validated risk models such as the PanCan malignancy risk model and agreed protocols for follow up of IPNs. This document highlights the importance of accessing prior imaging to assess for growth and accounting for technical differences between computed tomography (CT) scans. Any nodule considered to be growing requires discussion at a nodule MDM with decision to act for tissue biopsy as appropriate. A nodule MDM will assist in optimising the safest and most efficient biopsy techniques based on nodule characteristics and risk profile. By integrating multidisciplinary expertise and adhering to evidence‐based protocols, services can improve the timely diagnosis and management of IPNs, minimise over‐investigation, reduce chance of overdiagnosis and ultimately enhance patient outcomes and lung cancer survival.
- 29 May 2025
- Published by Wiley in Respirology
- Vol. 30 (7) , 558-573
Open AccessThe TSANZ Practical Guide for Clinicians in the Management of Screen‐ and Incidentally‐Detected Nodules
The increasing adoption of lung cancer screening programs and advancements in imaging technologies has significantly increased the detection of pulmonary nodules, both incidentally and through screening. This document provides a comprehensive guide for clinicians to address the complexities of managing indeterminate pulmonary nodules (IPNs), emphasising person‐centred and multidisciplinary care. IPNs are categorised based on size and morphology, with specific guidelines for malignancy risk stratification, diagnostic evaluation, and follow‐up. Dedicated lung nodule evaluation teams (LNETs) and nodule multidisciplinary meetings (MDMs) play a critical role in ensuring guideline adherence, streamlining the diagnostic pathway, reducing unnecessary investigations, and improving outcomes. Structured IPN programs have demonstrated benefits in early lung cancer detection, improved detection of early‐stage lung cancer, and reduced delays to treatment initiation. Effective management strategies include use of standardised reporting templates, utilising validated risk models such as the PanCan malignancy risk model and agreed protocols for follow up of IPNs. This document highlights the importance of accessing prior imaging to assess for growth and accounting for technical differences between computed tomography (CT) scans. Any nodule considered to be growing requires discussion at a nodule MDM with decision to act for tissue biopsy as appropriate. A nodule MDM will assist in optimising the safest and most efficient biopsy techniques based on nodule characteristics and risk profile. By integrating multidisciplinary expertise and adhering to evidence‐based protocols, services can improve the timely diagnosis and management of IPNs, minimise over‐investigation, reduce chance of overdiagnosis and ultimately enhance patient outcomes and lung cancer survival.
- 12 December 2024
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 69 (2) , 211
Lung cancer screening in Australia: The time approaches
- 12 December 2024
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 69 (2) , 211
Lung cancer screening in Australia: The time approaches
- Open Access
- 27 May 2024
- Published by Wiley in Respirology
- Vol. 29 (9) , 785-794
Chest x‐ray has low sensitivity to detect silicosis in artificial stone benchtop industry workers
Background and Objective: Chest x‐ray (CXR) remains a core component of health monitoring guidelines for workers at risk of exposure to crystalline silica. There has however been a lack of evidence regarding the sensitivity of CXR to detect silicosis in artificial stone benchtop industry workers.Methods: Paired CXR and high‐resolution computed tomography (HRCT) images were acquired from 110 artificial stone benchtop industry workers. Blinded to the clinical diagnosis, each CXR and HRCT was independently read by two thoracic radiologists from a panel of seven, in accordance with International Labour Office (ILO) methodology for CXR and International Classification of HRCT for Occupational and Environmental Respiratory Diseases. Accuracy of screening positive (ILO major category 1, 2 or 3) and negative (ILO major category 0) CXRs were compared with identification of radiological features of silicosis on HRCT.Results: CXR was positive for silicosis in 27/110 (24.5%) workers and HRCT in 40/110 (36.4%). Of the 83 with a negative CXR (ILO category 0), 15 (18.1%) had silicosis on HRCT. All 11 workers with ILO category 2 or 3 CXRs had silicosis on HRCT. In 99 workers ILO category 0 or 1 CXRs, the sensitivity of screening positive CXR compared to silicosis identified by HRCT was 48% (95%CI 29–68) and specificity 97% (90–100).Conclusion: Compared to HRCT, sensitivity of CXR was low but specificity was high. Reliance on CXR for health monitoring would provide false reassurance for many workers, delay management and underestimate the prevalence of silicosis in the artificial stone benchtop industry.
- 27 May 2024
- Published by Wiley in Respirology
- Vol. 29 (9) , 785-794
Open AccessChest x‐ray has low sensitivity to detect silicosis in artificial stone benchtop industry workers
Background and Objective: Chest x‐ray (CXR) remains a core component of health monitoring guidelines for workers at risk of exposure to crystalline silica. There has however been a lack of evidence regarding the sensitivity of CXR to detect silicosis in artificial stone benchtop industry workers.Methods: Paired CXR and high‐resolution computed tomography (HRCT) images were acquired from 110 artificial stone benchtop industry workers. Blinded to the clinical diagnosis, each CXR and HRCT was independently read by two thoracic radiologists from a panel of seven, in accordance with International Labour Office (ILO) methodology for CXR and International Classification of HRCT for Occupational and Environmental Respiratory Diseases. Accuracy of screening positive (ILO major category 1, 2 or 3) and negative (ILO major category 0) CXRs were compared with identification of radiological features of silicosis on HRCT.Results: CXR was positive for silicosis in 27/110 (24.5%) workers and HRCT in 40/110 (36.4%). Of the 83 with a negative CXR (ILO category 0), 15 (18.1%) had silicosis on HRCT. All 11 workers with ILO category 2 or 3 CXRs had silicosis on HRCT. In 99 workers ILO category 0 or 1 CXRs, the sensitivity of screening positive CXR compared to silicosis identified by HRCT was 48% (95%CI 29–68) and specificity 97% (90–100).Conclusion: Compared to HRCT, sensitivity of CXR was low but specificity was high. Reliance on CXR for health monitoring would provide false reassurance for many workers, delay management and underestimate the prevalence of silicosis in the artificial stone benchtop industry.
- 1 December 2005
- Published by Radiopaedia Australia Pty Ltd
Benign spiculation
- 1 December 2005
- Published by Radiopaedia Australia Pty Ltd
Solitary Fibrous Tumour of Pleura
- 1 December 2005
- Published by Radiopaedia Australia Pty Ltd
Acute Exacerbation IPF
- 1 December 2005
- Published by Radiopaedia Australia Pty Ltd
Atelectasis not ILD